| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2016: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2015: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
Fiscal Year 2014: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Outline of Final Research Achievements |
This study investigated to clarify the factors affecting the efficacy, adverse events, and pharmacokinetics of anti-coagulants, enoxaparin, fondaparinux and edoxaban in Japanese patients undergoing artificial total knee replacement surgery. We have revealed that the maximum plasma concentration of anti-coagulant may be a risk factor for subcutaneous hemorrhage and withdrawal of anti-coagulant. Population pharmacokinetic analysis showed that total clearance and volume of distribution of fondaparinux are affected by creatinine clearance and body weight, respectively.
|
